Adolescents and young adults are recommended to receive HPV vaccine from 9 years of age
Adolescents and young adults are recommended to receive HPV vaccine from 9 years of age and onwards. The optimal age for HPV vaccination is around 12–13 years prior to exposure to HPV. People who have not received HPV vaccine by 14 years of age can still receive the vaccine up to 25 years of age. However vaccination is most effective if the vaccine is given early in adolescence.
The recommended schedule for adolescents and young adults aged 9–25 years is 1 dose.1-4
People with immunocompromising conditions need 3 doses of HPV vaccine, regardless of their age (see Vaccination for people who are immunocompromised).
HPV vaccine is funded through the NIP for adolescents and young adults from 12 to 25 years of age. It is usually given to adolescents in School Year 7 (approximately 12–13 years). For details see the National Immunisation Program Schedule.
HPV vaccine may be considered in children aged <9 years who are at risk of exposure to HPV (for example, have a history of sexual abuse or have been diagnosed with a sexually transmitted infection). A subsequent dose should be given as routinely recommended at age ≥9 years, ideally at age 12–13 years.
Women who have received HPV vaccine are recommended to undergo cervical screening through the National Cervical Screening Program according to the Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding.5 HPV types other than those included in the HPV vaccines can cause cervical cancer. Therefore, both cervical screening and HPV vaccination are recommended. Healthcare providers should check on the need for catch-up vaccination at the first cervical screening visit, which should occur at age 25 years.